Midyear 2025 Biopharma Recap
Staying ahead means knowing the story behind the numbers. For the first time, Zymewire’s Midyear 2025 Biopharma Recap combines quantitative data with direct C-suite commentary from hundreds of executive earnings calls.
Explore key trends in biopharma funding and trial activity, now enriched with the strategic context you need. Understand the signals in the data and the strategy behind them to anticipate market shifts and act with confidence.
Download the Recap
Funding Review
Explore comprehensive breakdowns across North America, Europe, and APAC, highlighting key investment shifts year over year and quarter by quarter. With detailed analyses by company size, therapeutic area, and clinical development stage, quickly pinpoint where funding is flowing and identify your next strategic opportunity.
Unpacking Executive Commentary
For the first time, this report features insights pulled directly from biopharma executives. This new section leverages our integration of quarterly earnings call transcripts to uncover the qualitative story behind the industry's strategic moves. Analyzing commentary from leaders on the front lines adds a crucial layer of context, revealing not just what is happening, but why, and providing a deeper understanding of the opportunities ahead.
Upcoming Clinical Trials
Gain an exclusive, forward-looking view into upcoming clinical trial activity with Zymewire’s unique tracking of upcoming studies. Explore breakdowns by region, therapeutic area, and clinical trial phase to anticipate emerging opportunities. Leverage this early visibility and position your organization to capture outsourcing demand before the competition.
Study Initiations & Closeouts
Understanding study initiations and closeouts gives you an early edge. By spotting new trials as soon as they launch, you can monitor their progress closely, staying prepared to connect with sponsors when results emerge. Similarly, keeping track of completed studies, especially those with positive outcomes, offers valuable clues about where sponsors might head next.